MARKET WATCH: Johnson & Johnson's stock drops to pace Dow decliners after appeals court ruling on Zytiga disappoints
Shares of Johnson & Johnson JNJ, +0.03% fell 3.3% in afternoon trade, enough to pace declines among its health care peers and among the Dow Jones Industrial Average's DJIA, +1.46% components, after reports that an appeals court ruled that J&J can't block sales of generic Zytiga while the company appeals the overturning of a Zytiga patent.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
XLV in -0.73% downward trend, falling for three consecutive days on September 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XLV declined for three days, in 246 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for XLV moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 28 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 74 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 38 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
XLV moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 266 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 223 of 267 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement